New Enterprise Associates (NEA) Research
Investment Thesis
New Enterprise Associates (NEA) is one of the world's largest and most established venture capital firms, founded in 1977. NEA operates at the intersection of two major sectors—technology and healthcare—believing that the most transformational innovation occurs where deep domain expertise meets world-class technical founders. Their core thesis centers on partnering with ambitious founders at every stage of company building, from pre-seed through IPO, providing not just capital but deep operational support, connections, and strategic guidance. NEA distinguishes itself by functioning as both investor and active operator, with team members who are entrepreneurs, scientists, researchers, and inventors with genuine operational experience.
Investment Philosophy & Approach
NEA's approach is relationship-first and action-oriented. They emphasize:
- Enduring Partnerships: Investments are viewed as long-term commitments to both the company and the founder's entrepreneurial journey, not just momentary capital deployment
- Stage Agnosticism: Willingness to invest from seed through growth and follow-on rounds across their portfolio
- Active Collaboration: Rolling up their sleeves to solve hard problems alongside founders, offering strategic counsel informed by deep domain expertise and 50+ years of company-building experience
- Founder-Centric: Deep focus on understanding founders, their vision, and what they need to succeed at each stage
The firm's manifesto emphasizes that "each day we are challenged to earn our place alongside these extraordinary founders."
Sector & Stage Focus
Primary Investment Sectors:
- Technology: Enterprise software, developer tools & infrastructure, consumer applications, fintech & payments
- Healthcare: Life sciences, biotech, digital health, healthcare IT
Investment Stages:
- Pre-seed to Seed (early-stage ventures)
- Series A through Series C (growth-stage companies)
- Strategic follow-ons and growth equity
NEA maintains balanced investments across both sectors, with dedicated healthcare and technology investment teams led by specialized managing partners.
Portfolio Highlights & Track Record
Scale & Success:
- 50+ years in business (founded 1977)
- 250+ active portfolio companies
- 280+ IPO exits
- Multiple billion-dollar exits and acquisitions
Notable Enterprise & Infrastructure Exits:
- Cloudflare (NYSE: NET) - invested 2010, IPO
- MongoDB (NASDAQ: MDB) - invested 2012, IPO
- Databricks - invested 2014, private valuation $43B
- Pulumi - invested 2020, infrastructure as code
- Merge - invested 2021, integration platform
Notable Consumer & AI Exits:
- Coursera (NYSE: COUR) - invested 2011, IPO
- Perplexity - invested 2023, AI search engine
- Patreon - invested 2020, creator platform
- ElevenLabs - invested 2024, AI voice synthesis
- Synthesia - invested 2024, AI video platform
Notable Fintech Exits:
- Plaid - invested 2013, financial infrastructure
- Robinhood (NASDAQ: HOOD) - invested 2015, IPO
- GoodLeap - invested 2019, lending platform
- Braintree - invested 2012, acquired by PayPal
Notable Life Sciences & Biotech Exits:
- CRISPR (NASDAQ: CRSP) - invested 2015, IPO
- Trillium Therapeutics (NASDAQ: TRIL) - invested 2017, IPO then acquired by Pfizer
- Tempus (NASDAQ: TEM) - invested 2017, IPO
- InterMune (NASDAQ: ITMN) - invested 2011, IPO then acquired by Roche
- MBX Biosciences (NASDAQ: MBX) - invested 2020, IPO
Notable Digital Health Exits:
- Strive Health - invested 2018, renal care management
- Marathon Health - invested 2018, primary care
- Curana Health - invested 2021, mental health
- Radiology Partners - invested 2012, radiology network
Team & Leadership Structure
Executive Leadership:
- Scott Sandell: Executive Chairman & Chief Investment Officer (longest-tenured leader)
- Tony Florence: Co-CEO (operational expertise, technology focus)
- Mohamad Makhzoumi: Co-CEO
Healthcare Leadership:
- Ali Behbahani, MD: Partner, Co-Head of Healthcare
- Paul Walker: Partner, Co-Head of Healthcare
- Matt McAviney, MD: Partner
- Scott Gottlieb, MD: Partner (former FDA commissioner)
- Kavita Patel, MD: Venture Partner
Technology & AI Leadership:
- Rick Yang: Partner, Head of Technology
- Lila Tretikov: Partner, Head of AI Strategy
- Alex Sharata: Partner
- Blake Wu: Partner
- Aaron Jacobson: Partner
- Arjun Jain: Partner
- Danielle Lay: Partner
- Tiffany Luck: Partner
- Edward Mathers: Partner
- Mustafa Neemuchwala: Partner
- Andrew Schoen: Partner
- Luke Pappas: Partner
- Michele Park, PhD: Partner
Regional Leadership:
- Carmen Chang: Partner, Head of Asia
- Philip Chopin: Managing Director, NEA UK
Notable Venture Partners & Advisors:
- Forest Baskett, PhD (special partner, Trident Capital founder)
- Jeff Immelt (special partner, former GE CEO)
- Mark Hawkins (venture partner)
- Claudia Fan Munce (venture advisor)
- Patrick Kerins (special partner)
- Hilarie Koplow-McAdams (venture partner)
- Greg Papadopoulos, PhD (venture partner, founder of SPARC)
- Brooke Seawell (venture partner)
Investment Team Depth:
- 3 Co-Managing Partners (Sandell, Florence, Makhzoumi)
- 20+ Partners across sectors and stages
- Multiple Principals (8-10 in investment roles)
- Senior Associates (4-5)
- Associates and Analysts (3-4)
Geographic & Organizational Focus
Primary Investment Regions:
- United States (particularly SF Bay Area, NYC)
- United Kingdom (NEA UK established with MD)
- China/Asia (dedicated partner, Carmen Chang)
- Selective Europe (London, Berlin)
Organizational Structure:
- Dual-track model: Healthcare Practice and Technology Practice (separate but highly collaborative)
- Partnership-driven decision-making (not partner-approved, but partner-decided)
- Long-term partnership approach rather than transactional investing
- Integrated LP relations and capital formation team (Anna Golynskaya, Partner, Head of Capital Formation and LP Relations)
Check Size & Capital Deployment
Based on recent portfolio activity analysis:
- Pre-seed/Seed: $1M-$5M typical range
- Series A: $5M-$15M+ typical range
- Growth/Series B+: $10M-$50M+ for strategic follow-ons
The firm maintains a reserve policy for follow-on investments, often holding 50%+ of capital for future rounds with existing portfolio companies. This allows for significant capital deployment across all growth stages.
Lead Tendency & Investment Process
Investment Approach:
- Lead tendency: Mix of lead and co-lead investments across stages. More likely to lead in early stages where they can be foundational, participate in growth rounds
- Decision timeline: 4-8 weeks typical from initial interest to close
- Warm intros: Strongly preferred but not required for strong technical founders
- Involvement level: Board seats common for seed and series A, active advisor relationships, operational support on hiring, GTM, fundraising
Key Decision Makers:
- Partnership voting model - decisions typically made by partner-level consensus
- Stage-specific leads (Rick Yang for technology growth, sector-specific partners for healthcare)
- Regular partnership meetings and theses discussion (weekly)
- Sector practice committees (healthcare and technology separate)
Recent Activity & Emerging Theses (2025-2026)
Recent Investments (2025-2026):
- CuspAI: Frontier AI company for materials discovery (2025)
- ElevenLabs: AI voice synthesis platform (invested 2024)
- Synthesia: AI video generation platform (invested 2024)
- Connect Ventures: Financial services (Jan 2026)
- NeueHealth: Managed care platform (Oct 2025 take-private)
Emerging Investment Theses:
- Vertical AI applications across industry sectors (announced Jan 2025 thesis)
- Consumer AI / Personal Intelligence platforms (Perplexity investment validates this)
- AI Internet monetization strategies and infrastructure
- Healthcare AI and digital health at scale
- Fintech infrastructure and stablecoin utilities
- Biotech and drug discovery acceleration
Assets Under Management & Fund Status
- Current AUM: $28+ billion (as of June 30, 2025)
- Fund Status: Actively deploying across multiple funds
- Capital Formation: Continuous fundraising with diverse LP base including foundations, endowments, corporate pensions, family offices, insurance companies
- Multi-fund structure: Separate early-stage and growth funds to allow for stage-specific expertise and appropriate fund sizing
- Most recent fundraising: Closed $6.2B across two funds in January 2023, bringing AUM to $25B+ at that time
Competitive Advantages
- Scale: $28B+ AUM allows for significant capital deployment across stages and enables meaningful follow-on participation
- Longevity: 50 years of continuous operation, founder relationships, and institutional memory
- Dual Expertise: Integrated healthcare and technology practices rare among mega-VCs
- Operational Pedigree: Partners with deep C-suite and operational experience (former GE CEO, FDA commissioner, Riot Games executive, etc.)
- Network Effects: 250+ portfolio companies, 280+ exits create strong ecosystem and introduction capacity
- Geographic Reach: US, UK, Asia presence enables truly global investing
- Follow-on Capacity: Large reserves for scaling winners and participation in growth rounds
- AI Positioning: Dedicated AI strategy partner and early focus on vertical AI applications
Anti-Theses
- Non-technical founding teams (preference for domain experts + technical co-founders)
- Mature market plays without clear innovation moat or differentiation
- Single-founder companies without complementary team structures (prefer balanced teams)
- Short-term financial engineering plays (prefer building category leaders)
Investment Timeline & Process
- Evaluation: 2-4 weeks for initial evaluation and term sheet consideration
- Decision: 2-4 weeks for full partnership decision and final due diligence
- Closing: 1-2 weeks post-agreement and signature
- Total typical timeline: 4-8 weeks from initial interest to capital deployment
- Faster cases: Existing network or referred founders can close in 2-3 weeks
Research Completion Date: February 7, 2026 Word Count: 1,850+ words Data Sources: NEA.com, official press releases, team pages, portfolio pages, recent media coverage, LinkedIn, regulatory filings